Hot Casino Stocks To Buy Right Now

“Formula for success: rise early, work hard, strike oil” – J. Paul Getty

I must confess to feeling kind of lonely at times this year being one of a handful of observers of the casino space, (and at times, the only one,) standing firm on my undiminished faith that Las Vegas Sands (NYSE:LVS) valuations were dead wrong. Now, after the Macau Parisian has opened and LVS Q3 results knocked it out of the park I suddenly have lots of company. I’m bemused to see the bandwagon suddenly getting rather crowded.

There’s no room for gloat or vapid vainglory in my gene pool. I’ve had my share of missed calls – but the casino space is my home stamping grounds. But it is fair to point out that many prophets of doom since the 2015 junket crackdown ran for the exits or pooh-poohed my consistent call on SA that LVS was still worth $70 in my view. Others agreed with me but were less bullish on price. We’re not there yet to be certain. But as I have written before, if the trade holds steady at $60 or above, I feel the ramp-up to $70 or possibly higher by Q2 2017 will move into the speed lane.

Hot Casino Stocks To Buy Right Now: Ionis Pharmaceuticals, Inc.(IONS)

Advisors’ Opinion:

  • [By George Budwell]

    Biogen’s top-line growth has now become almost totally dependent on sales of its fairly new spinal muscular atrophy (SMA) drug, Spinraza, that it co-developed with Ionis Pharmaceuticals (NASDAQ:IONS).

  • [By Keith Speights]

    Research and development is the lifeblood of biotech companies. The potential for new drugs also serves as a primary factor driving biotech stocks higher and higher. That’s been the case for Celgene (NASDAQ:CELG), Ionis Pharmaceuticals (NASDAQ:IONS), and Ligand Pharmaceuticals (NASDAQ:LGND).

  • [By Brian Orelli]

    Ionis Pharmaceuticals (NASDAQ:IONS) gave investors an update on its pipeline today with a slide deck that contained a whopping 65 entries. The whole presentation is worth a listen, but here are the five slides investors absolutely must see.

  • [By WWW.THESTREET.COM]

    Coming up in this episode of Mad Money: Cramer interviews Dr. Stanley Crooke, CEO of Ionis Pharmaceuticals (IONS) . And, here’s Cramer’s read on Trump’s view of China. Plus, don’t miss the Lightning Round. Which stocks in Cramer bullish on?

Hot Casino Stocks To Buy Right Now: Rite Aid Corporation(RAD)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Cramer was bearish on Hertz Global Holdings (HTZ) , General Motors (GM) , Pandora Media (P) , Cedar Fair (FUN) , Quotient Technology (QUOT) and Rite Aid (RAD) .

  • [By Paul Ausick]

    Rite Aid Corp. (NYSE: RAD) dropped about 0.9% Thursday, to post a new 52-week low of $4.61 after closing at $4.65 on Wednesday. The stock’s 52-week high is $8.77. Volume was about 10% below the daily average of around 25.8 million shares. The company had no specific news.

  • [By Paul Ausick]

    Rite Aid Corp. (NYSE: RAD) dropped about 4.6% Monday, to post a new 52-week low of $5.20 after closing at $5.45 on Friday. The stock’s 52-week high is $8.77. Volume was about 15% above the daily average of around 24.4 million shares. The company had no specific news.

  • [By Jon C. Ogg]

    Rite Aid Corp. (NYSE: RAD) is finding itself in an odd situation. After a failed merger that crushed its stock, Rite Aid may never be able to get back to its highs of recent years, now that it has been shrinking its footprint. Or is that view false?

  • [By Paul Ausick]

    Rite Aid Corp. (NYSE: RAD) dropped about 2.6% Monday to post a new 52-week low of $3.70 after closing at $3.80 on Friday. The stock’s 52-week high is $8.77. Volume was nearly equal to the daily average of more than 23 million shares traded. The company reports fiscal fourth-quarter results after markets closed on Tuesday, but investors are waiting for an FTC decision on the Walgreens merger.

  • [By Chris Lange]

    Rite Aid Corp. (NYSE: RAD) fiscal third-quarter report is scheduled for late on Wednesday. Consensus estimates are calling for a net loss of $0.02 per share and $7.45 billion in revenue. The shares closed trading at $1.97 apiece on Friday. The consensus price target is $2.11, and the 52-week trading range is $1.38 to $8.77.

Hot Casino Stocks To Buy Right Now: Qorvo, Inc.(QRVO)

Advisors’ Opinion:

  • [By ]

    TSMC fell 5.7% on Wednesday in response to the news. Apple, which relies on TSMC to manufacture its A-series system-on-chips (SoCs) and various other chips, fell 2.8%. iPhone/iPad chip suppliers such as Cirrus Logic (CRUS) , Broadcom (AVGO) , Skyworks (SWKS) and Qorvo (QRVO) , some of which also rely on TSMC, registered 3%-plus drops.

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday's regular session.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Monday was Qorvo, Inc. (NASDAQ: QRVO) which jumped about 5.5% to $71.53. The stocks 52-week range is $45.00 to $72.42. Volume was 3.8 million which is above the daily average 1.5 million shares.

Hot Casino Stocks To Buy Right Now: American International Group Inc.(AIG)

Advisors’ Opinion:

  • [By Lisa Levin]

     

    Losers
    Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering.
    InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday.
    Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81.
    Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections.
    Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results.
    LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss.
    Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit.
    Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings.
    Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss.
    Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight.
    Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings.
    The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results.
    Arcadia Biosciences, Inc. (N

  • [By Ben Levisohn]

    Heading into its earnings following the close of trading yesterday, shares of American International Group (AIG) had gained 34% from its low on Jun. 28 to Feb. 14. Then the bottom fell out.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on American International Group (AIG)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ben Levisohn]

    BMO’s Charles Sebaski explains why he upgraded American International Group (AIG) to Outperform from market Perform:

    Agence France-Presse/Getty Images

    AIG has been trading at discount to its tangible book given its mid-single digit return profile; however, we expect AIGs valuation to keep increasing with its improving return profile. We are now forecasting AIG to generate a 9.9% operating return on tangible common equity (ROtE) in 2018, which would be a 450 bp improvement from 2016. A double-digit return profile warrants the 1x multiple that we are applying to its tangible book value per share. While we expect AIGs return profile to benefit from lower taxes, we also expect the companys life and retirement business to improve from the rising interest rates as those spread businesses are more interest rate sensitive than the P&C business. That said, we expect continued improvement on both the loss and expense sides of the P&C as contributing factors to the ROtE improve.

    BMO also upgraded Arch Capital Group (ACGL), Brown & Brown (BRO), and Travelers (TRV).

    Shares of American International Group have declined 0.4% to $65.60 at 3:36 p.m. today, whileArch Capital Group has gained 2% to $87.90,Brown & Brown has advanced 0.5% to $44.65, andTravelers has risen 1.3% to $120.79.

Hot Casino Stocks To Buy Right Now: Genfit SA (GNFTF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    In a recent article, we discussed what makes Genfits (OTCPK:GNFTF) Elafibranor one of the most promising candidates in the NASH treatment development space. Given the unmet need (no approved therapies), Elafibranors mechanism of action and the potential it has shown in clinical stages, we see a strong chance of approval if the pivotal Phase 3 study succeeds. In this article, we will briefly discuss the chances of Elafibranors success in clinical stages and Genfits valuation based on the potential of its lead product candidate. We will briefly also discuss the risks to the investment thesis.

Hot Casino Stocks To Buy Right Now: Zumiez Inc.(ZUMZ)

Advisors’ Opinion:

  • [By Lisa Levin]

    Zumiez Inc. (NASDAQ: ZUMZ) was down, falling around 12 percent to $19.15. Zumiez reported in-line earnings for its third quarter on Thursday.

    Commodities

  • [By Lisa Levin]

    Zumiez Inc. (NASDAQ: ZUMZ) was down, falling around 10 percent to $19.78. Zumiez reported in-line earnings for its third quarter on Thursday.

    Commodities

  • [By Chris Lange]

    Zumiez Inc. (NASDAQ: ZUMZ) is set to report its fiscal second-quarter results on Thursday. The consensus estimates predicta net loss of $0.08 per share and $177.35 million in revenue. Shares were changing hands at $16.61 on Fridays close. The consensus price target is $15.20, and the stock has a 52-week range of $11.53 to $23.45.

  • [By Dan Caplinger]

    Friday was a good day on Wall Street, as the stock market responded favorably to encouraging news on the employment front. The U.S. unemployment rate dropped on fairly strong job creation during the month of February, and that helped push the Dow, S&P 500, and Nasdaq Composite to modest gains of roughly between a quarter percent and a half percent. Yet even with a positive mood among market participants, some stocks weren’t able to participate in the end-of-week rally. Finisar (NASDAQ:FNSR), Zumiez (NASDAQ:ZUMZ), and Winnebago Industries (NYSE:WGO) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.